Amylyx Pharmaceuticals, a fast-rising biotech company that went public last month, created the role of chief legal officer and filled it with Gina Mazzariello, who has more than two decades of legal experience in the health care industry.

Cambridge, Massachusetts-based Amylyx, founded in 2013, is a clinical-stage company that aims to treat amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease, by addressing the death of neurons. It raised $190 million in its initial public offering and now has a market value of $1.7 billion.